Entera Bio Ltd. Selling, General and Administrative (SG&A) Expenses Growth

Selling, General and Administrative (SG&A) Expenses Growth of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Selling, General and Administrative (SG&A) Expenses Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Selling, General and Administrative (SG&A) Expenses Growth for the quarter ending September 29, 2020 was -22.74% (a -115.71% decrease compared to previous quarter)
  • Year-over-year quarterly Selling, General and Administrative (SG&A) Expenses Growth decreased by -135.5%
  • Annual Selling, General and Administrative (SG&A) Expenses Growth for 2019 was 50.58% (a -175.66% decrease from previous year)
  • Twelve month Selling, General and Administrative (SG&A) Expenses Growth ending September 29, 2020 was 40.53% (a -14.98% decrease compared to previous quarter)
  • Twelve month trailing Selling, General and Administrative (SG&A) Expenses Growth decreased by -19.87% year-over-year
Trailing Selling, General and Administrative (SG&A) Expenses Growth for the last four month:
29 Sep '20 29 Jun '20 30 Mar '20 30 Dec '19
40.53% 47.67% 71.28% 50.58%
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Selling, General and Administrative (SG&A) Expenses Growth of Entera Bio Ltd.

Most recent Selling, General and Administrative (SG&A) Expenses Growthof ENTX including historical data for past 10 years.

Interactive Chart of Selling, General and Administrative (SG&A) Expenses Growth of Entera Bio Ltd.

Entera Bio Ltd. Selling, General and Administrative (SG&A) Expenses Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -22.74% 144.75% 22.16%
2019 64.05% 1.23% 253.55% -16.39% 50.58%
2018 -66.85%

Business Profile of Entera Bio Ltd.

Sector: Healthcare
Industry: Biotechnology
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase II clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. The company was founded in 2009 and is based in Jerusalem, Israel.